

Klaus Seppi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/719223/klaus-seppi-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

272
papers

16,093
citations

67
h-index

120
g-index

298
ext. papers

20,078
ext. citations

6.5
avg, IF

6.39
L-index

#	Paper	IF	Citations
272	Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17013	51.1	1700
271	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017 , 32, 853-864	7	840
270	A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. <i>American Journal of Human Genetics</i> , 2011 , 89, 168-75	11	624
269	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26 Suppl 3, S42-80	7	599
268	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26 Suppl 3, S2-41	7	397
267	Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). <i>Movement Disorders</i> , 2004 , 19, 1391-402	7	372
266	Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. <i>Movement Disorders</i> , 2019 , 34, 180-198	7	357
265	International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1248-1267	7	323
264	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology</i> , 2013 , 12, 264-74	24.1	322
263	The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). <i>Movement Disorders</i> , 2015 , 30, 229-37	7	313
262	Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. <i>Lancet Neurology</i> , 2010 , 9, 1070-7	24.1	305
261	Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. <i>Lancet Neurology</i> , 2005 , 4, 815-20	24.1	215
260	Seminar on choreas. <i>Lancet Neurology</i> , 2006 , 5, 589-602	24.1	213
259	Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. <i>Annals of Neurology</i> , 2005 , 58, 630-4	9.4	172
258	White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. <i>Annals of Neurology</i> , 2011 , 69, 400-7	9.4	171
257	Red flags for multiple system atrophy. <i>Movement Disorders</i> , 2008 , 23, 1093-9	7	168
256	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurology</i> , 2017 , 16, 701-711	24.1	161

255	Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010 , 25, 2604-12	7	155
254	Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. <i>Movement Disorders</i> , 2014 , 29, 857-67	7	148
253	The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1460-1477	5.3	142
252	Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. <i>Neurology</i> , 2015 , 84, 654-8	6.5	137
251	Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). <i>Movement Disorders</i> , 2010 , 25, 97-107	7	136
250	Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 1357-63	7	135
249	Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2003 , 18, 1132-8	7	135
248	Grading of neuropathology in multiple system atrophy: proposal for a novel scale. <i>Movement Disorders</i> , 2005 , 20 Suppl 12, S29-36	7	132
247	Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. <i>Archives of Neurology</i> , 2011 , 68, 932-7		131
246	The Concept of Prodromal Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015 , 5, 681-97	5.3	128
245	Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. <i>NeuroImage</i> , 2004 , 21, 1443-51	7.9	127
244	Differentiation of malignant and benign musculoskeletal tumors: combined color and power Doppler US and spectral wave analysis. <i>Radiology</i> , 2002 , 223, 410-6	20.5	123
243	Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. <i>Circulation</i> , 2007 , 116, 385-91	16.7	122
242	Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. <i>Movement Disorders</i> , 2009 , 24, 949-64	7	119
241	Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). <i>Movement Disorders</i> , 2006 , 21, 179-86	7	114
240	Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2017 , 82, 419-428	9.4	108
239	Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. <i>Brain</i> , 2006 , 129, 538-42	11.2	108
238	Magnetic resonance imaging for the diagnosis of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017 , 124, 915-964	4.3	106

237	Prevalence and burden of gait disorders in elderly men and women aged 60-97 years: a population-based study. <i>PLoS ONE</i> , 2013 , 8, e69627	3.7	103
236	Voxel based morphometry reveals specific gray matter changes in primary dystonia. <i>Movement Disorders</i> , 2007 , 22, 1538-42	7	102
235	Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. <i>Brain</i> , 2005 , 128, 1605-12	11.2	102
234	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1601-1608	7	101
233	Restless legs syndrome in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 2076-80	7	100
232	Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study. <i>Journal of Neurology</i> , 2007 , 254, 191-6	5.5	100
231	Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 619-623	7	96
230	Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. <i>Movement Disorders</i> , 2015 , 30, 1068-76	7	96
229	Enteric nervous system α -synuclein immunoreactivity in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2015 , 85, 1761-8	6.5	94
228	Mortality in Parkinson's disease: a 20-year follow-up study. <i>Movement Disorders</i> , 2009 , 24, 819-25	7	91
227	Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 216-9	7	90
226	Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. <i>Neurodegenerative Diseases</i> , 2010 , 7, 300-18	2.3	89
225	Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. <i>NeuroImage</i> , 2006 , 31, 240-5	7.9	84
224	An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. <i>Current Opinion in Neurology</i> , 2005 , 18, 370-5 ^{7.1}	7.1	84
223	Health-related quality of life in multiple system atrophy. <i>Movement Disorders</i> , 2006 , 21, 809-15	7	83
222	Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2009 , 24, 1906-9	7	80
221	Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. <i>Neuroimaging Clinics of North America</i> , 2010 , 20, 29-55	3	79
220	Mortality in Parkinson's disease: a 38-year follow-up study. <i>Movement Disorders</i> , 2015 , 30, 266-9	7	78

219	Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. <i>Movement Disorders</i> , 2004 , 19, 1438-45	7	78
218	Treatment of dementia in Parkinson's disease. <i>The Cochrane Library</i> , 2019 ,	5.2	78
217	Treatment of psychosis in Parkinson's disease. <i>The Cochrane Library</i> , 2019 ,	5.2	78
216	Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease. <i>Brain</i> , 2012 , 135, 3348-54	4.1	73
215	Diffusion weighted imaging best discriminates PD from MSA-P: A comparison with tilt table testing and heart MIBG scintigraphy. <i>Movement Disorders</i> , 2007 , 22, 1771-6	7	73
214	Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. <i>Movement Disorders</i> , 2006 , 21, 1109-13	7	73
213	Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. <i>Journal of Neurology</i> , 2002 , 249, 835-41	5.5	73
212	Probable RBD and association with neurodegenerative disease markers: A population-based study. <i>Movement Disorders</i> , 2015 , 30, 1417-21	7	71
211	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , 2015 , 14, 145-52	24.1	69
210	Video-EEG monitoring: safety and adverse events in 507 consecutive patients. <i>Epilepsia</i> , 2011 , 52, 443-52	5.4	69
209	Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2016 , 79, 1026-30	9.4	68
208	Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked. <i>Parkinsonism and Related Disorders</i> , 2017 , 40, 1-10	3.6	67
207	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1643-1646	7	67
206	Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson's disease. <i>Sleep Medicine</i> , 2015 , 16, 186-9	4.6	67
205	Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy. <i>Orphanet Journal of Rare Diseases</i> , 2014 , 9, 161	4.2	67
204	The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. <i>Movement Disorders</i> , 2017 , 32, 510-525	7	65
203	Riluzole in Huntington's disease (HD): an open label study with one year follow up. <i>Journal of Neurology</i> , 2001 , 248, 866-9	5.5	63
202	Cortical atrophy in the cerebellar variant of multiple system atrophy: a voxel-based morphometry study. <i>Movement Disorders</i> , 2006 , 21, 159-65	7	61

201	Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2010 , 25, 2444-9	7	60
200	Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. <i>Neurology</i> , 2016 , 86, 1242-9	6.5	60
199	Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2014 , 29, 1774-80	7	58
198	Which dyskinesia scale best detects treatment response?. <i>Movement Disorders</i> , 2013 , 28, 341-6	7	58
197	Predictors of survival in dementia with lewy bodies and Parkinson dementia. <i>Neurodegenerative Diseases</i> , 2007 , 4, 428-30	2.3	58
196	Genome-wide association study in essential tremor identifies three new loci. <i>Brain</i> , 2016 , 139, 3163-3169 ^{1,2}		57
195	Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. <i>Movement Disorders</i> , 2003 , 18, 319-323	7	57
194	Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community. <i>Movement Disorders</i> , 2016 , 31, 1405-8	7	57
193	Cause-specific mortality among patients with epilepsy: results from a 30-year cohort study. <i>Epilepsia</i> , 2013 , 54, 495-501	6.4	55
192	Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. <i>Movement Disorders</i> , 2006 , 21, 847-52	7	55
191	Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. <i>Archives of Neurology</i> , 2006 , 63, 1154-60		52
190	Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. <i>European Heart Journal</i> , 2005 , 26, 279-87	9.5	52
189	International Guidelines for the Treatment of Huntington's Disease. <i>Frontiers in Neurology</i> , 2019 , 10, 710	4.1	51
188	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. <i>Lancet Neurology</i> , 2019 , 18, 165-176 ¹		50
187	Cause-specific mortality in adult epilepsy patients from Tyrol, Austria: hospital-based study. <i>Journal of Neurology</i> , 2015 , 262, 126-33	5.5	48
186	Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease. <i>Brain</i> , 2013 , 136, 3028-37	11.2	47
185	Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study. <i>Journal of Neurology</i> , 2010 , 257, 638-45	5.5	47
184	Progression of parkinsonism in multiple system atrophy. <i>Journal of Neurology</i> , 2005 , 252, 91-6	5.5	47

183	Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. <i>European Journal of Neurology</i> , 2021 , 28, 3348-3359	6	46
182	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019 , 34, 975-984	7	44
181	Characterizing advanced Parkinson's disease: OBSERVE-PD observational study results of 2615 patients. <i>BMC Neurology</i> , 2019 , 19, 50	3.1	44
180	The reorganization of functional architecture in the early-stages of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018 , 50, 61-68	3.6	42
179	Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1408-13	7	41
178	Update on diffusion MRI in Parkinson's disease and atypical parkinsonism. <i>Journal of the Neurological Sciences</i> , 2013 , 332, 21-9	3.2	40
177	Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. <i>Movement Disorders</i> , 2015 , 30, 1885-92	7	40
176	Potential of advanced MR imaging techniques in the differential diagnosis of parkinsonism. <i>Movement Disorders</i> , 2009 , 24 Suppl 2, S711-20	7	39
175	Freezing of gait in postmortem-confirmed atypical parkinsonism. <i>Movement Disorders</i> , 2002 , 17, 1041-5	7	39
174	Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 536-544	2.2	38
173	Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson's Disease: A Cross-Sectional Study. <i>Gerontology</i> , 2019 , 65, 216-228	5.5	38
172	Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. <i>CNS Drugs</i> , 2019 , 33, 905-918	6.7	37
171	Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. <i>Movement Disorders</i> , 2010 , 25, 1464-9	7	37
170	Brain structural profile of multiple system atrophy patients with cognitive impairment. <i>Journal of Neural Transmission</i> , 2017 , 124, 293-302	4.3	36
169	Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease. <i>Human Genetics</i> , 2006 , 120, 285-92	6.3	36
168	Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]ECIT SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 1012-20	8.8	35
167	Diffusion-weighted imaging in Huntington's disease. <i>Movement Disorders</i> , 2006 , 21, 1043-7	7	35
166	Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. <i>NeuroReport</i> , 2004 , 15, 1711-4	1.7	35

165	Multiple system atrophy. <i>International Review of Neurobiology</i> , 2019 , 149, 137-192	4.4	35
164	Alpha-synuclein immunoreactivity patterns in the enteric nervous system. <i>Neuroscience Letters</i> , 2015 , 602, 145-9	3.3	34
163	Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study. <i>Movement Disorders</i> , 2017 , 32, 1457-1464	7	34
162	An open trial of levetiracetam for segmental and generalized dystonia. <i>Movement Disorders</i> , 2007 , 22, 1649-51	7	34
161	Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study. <i>Movement Disorders</i> , 2018 , 33, 405-413	7	33
160	Towards translational therapies for multiple system atrophy. <i>Progress in Neurobiology</i> , 2014 , 118, 19-35	10.9	33
159	Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2007 , 25, 564-9	5.6	33
158	MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. <i>Parkinsonism and Related Disorders</i> , 2018 , 46, 47-55	3.6	33
157	White and gray matter abnormalities in narcolepsy with cataplexy. <i>Sleep</i> , 2012 , 35, 345-51	1.1	30
156	Abnormalities of dopaminergic neurotransmission in SCA2: a combined 123I-betaCIT and 123I-IBZM SPECT study. <i>Movement Disorders</i> , 2004 , 19, 1320-5	7	30
155	The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2018 , 54, 90-94	3.6	29
154	Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?. <i>Neurology</i> , 2016 , 87, 36-40	6.5	29
153	Risk factors and prodromal markers and the development of Parkinson's disease. <i>Journal of Neurology</i> , 2014 , 261, 180-7	5.5	29
152	Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy. <i>Movement Disorders</i> , 2007 , 22, 1822-4	7	29
151	Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. <i>Parkinsonism and Related Disorders</i> , 2018 , 52, 83-89	3.6	28
150	Sensor-based gait analysis in atypical parkinsonian disorders. <i>Brain and Behavior</i> , 2018 , 8, e00977	3.4	28
149	Exaggerated auditory startle responses in multiple system atrophy: a comparative study of parkinson and cerebellar subtypes. <i>Clinical Neurophysiology</i> , 2003 , 114, 541-7	4.3	28
148	Computerized tremor analysis of valproate-induced tremor: a comparative study of controlled-release versus conventional valproate. <i>Epilepsia</i> , 2005 , 46, 320-3	6.4	28

147	Development and Validation of the Automated Imaging Differentiation in Parkinsonism (AID-P): A Multi-Site Machine Learning Study. <i>The Lancet Digital Health</i> , 2019 , 1, e222-e231	14.4	27
146	Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7T MRI. <i>Neurology</i> , 2014 , 82, 1752	6.5	27
145	Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease?. <i>Movement Disorders</i> , 2012 , 27, 1182-5	7	27
144	Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy. <i>NeuroImage</i> , 2003 , 20, 1253-63	7.9	27
143	Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017 , 12, e0189897	3.7	26
142	Nonmotor symptoms in subjects without evidence of dopaminergic deficits. <i>Movement Disorders</i> , 2015 , 30, 976-81	7	26
141	Substantia nigra hyperechogenicity as a marker for Parkinson's disease: a population-based study. <i>Neurodegenerative Diseases</i> , 2013 , 12, 212-8	2.3	26
140	Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. <i>Brain</i> , 2021 , 144, 1118-1126	11.2	26
139	A novel computer-assisted image analysis of [123I]ECIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011 , 38, 702-10	8.8	25
138	Parkinson's disease and arithmetics: the role of executive functions. <i>Journal of the Neurological Sciences</i> , 2006 , 248, 124-30	3.2	25
137	Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 156-160	2.2	25
136	Deep brain stimulation in Huntington's disease: A 4-year follow-up case report. <i>Movement Disorders</i> , 2012 , 27, 806-7; author reply 807-8	7	24
135	Levodopa-induced sleepiness in the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2006 , 21, 1281-3	7	24
134	Riluzole therapy in cervical dystonia. <i>Movement Disorders</i> , 2002 , 17, 198-200	7	23
133	Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. <i>Annals of Neurology</i> , 2020 , 88, 712-722	9.4	23
132	Auditory startle response in cervical dystonia. <i>Movement Disorders</i> , 2003 , 18, 1522-6	7	22
131	Structural Imaging in Atypical Parkinsonism. <i>International Review of Neurobiology</i> , 2018 , 142, 67-148	4.4	22
130	Predictors for mild parkinsonian signs: a prospective population-based study. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 321-4	3.6	21

129	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. <i>Journal of Neural Transmission</i> , 2016 , 123, 439-45	4.3	21
128	Neuroimaging: current role in detecting pre-motor Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 634-43	7	21
127	The influence of deep brain stimulation on pain perception in Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 1367-8; author reply 1368-9	7	21
126	Seeing ophthalmologic problems in Parkinson disease: Results of a visual impairment questionnaire. <i>Neurology</i> , 2020 , 94, e1539-e1547	6.5	20
125	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. <i>Movement Disorders</i> , 2020 , 35, 976-983	7	20
124	Cannabinoids for Treatment of Dystonia in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2018 , 7, 167-173	1.9	19
123	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.. <i>Movement Disorders</i> , 2022 ,	7	19
122	Multiple system atrophy as emerging template for accelerated drug discovery in Synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 793-9	3.6	18
121	An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. <i>Proteome Science</i> , 2012 , 10, 71	2.6	18
120	Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018 , 49, 81-87	3.6	17
119	Orthostatic hypotension is differentially associated with the cerebellar versus the parkinsonian variant of multiple system atrophy: a comparative study. <i>Cerebellum</i> , 2012 , 11, 223-6	4.3	17
118	Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease. <i>Annals of Neurology</i> , 2021 , 90, 62-75	9.4	17
117	Early distinction of Parkinson-variant multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 440-441	7	17
116	Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. <i>Movement Disorders</i> , 2019 , 34, 1041-1048	7	16
115	Drug safety evaluation of rotigotine. <i>Expert Opinion on Drug Safety</i> , 2012 , 11, 503-12	4.1	16
114	A follow-up study of substantia nigra echogenicity in healthy adults. <i>Movement Disorders</i> , 2012 , 27, 1196-7		16
113	MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice. <i>Parkinsonism and Related Disorders</i> , 2007 , 13 Suppl 3, S400-5	3.6	16
112	Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy (MSA): placebo-controlled, polysomnographic case report. <i>Movement Disorders</i> , 2001 , 16, 1177-9		15

111	Consistency of "Probable RBD" Diagnosis with the RBD Screening Questionnaire: A Follow-up Study. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 403-405	2.2	14
110	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019 , 11, 301-309	5.2	14
109	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 33-40	3.6	14
108	Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy). <i>Experimental Neurology</i> , 2000 , 164, 166-75	5.7	14
107	Midbrain hyperechogenicity, hyposmia, mild parkinsonian signs and risk for incident Parkinson's disease over 10 years: A prospective population-based study. <i>Parkinsonism and Related Disorders</i> , 2020 , 70, 51-54	3.6	14
106	IgLON5 autoimmunity tested negative in patients with progressive supranuclear palsy and corticobasal syndrome. <i>Parkinsonism and Related Disorders</i> , 2017 , 38, 102-103	3.6	13
105	Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. <i>Parkinsonism and Related Disorders</i> , 2019 , 67, 60-65	3.6	13
104	Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD). <i>PLoS ONE</i> , 2015 , 10, e0145493	3.7	13
103	Is transcranial sonography useful to distinguish drug-induced parkinsonism from Parkinson's disease?. <i>Movement Disorders</i> , 2012 , 27, 1194-6	7	13
102	Clinical and neuropathological correlates of Lewy body disease. <i>Acta Neuropathologica</i> , 2003 , 106, 188-9; author reply 190	14.3	13
101	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 750-762	2.2	13
100	Cognition in multiple system atrophy: a single-center cohort study. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 219-228	5.3	12
99	Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2019 , 58, 23-27	3.6	12
98	The Unified Multiple System Atrophy Rating Scale: intrarater reliability. <i>Movement Disorders</i> , 2012 , 27, 1683-5	7	12
97	Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor. <i>Movement Disorders</i> , 2016 , 31, 579-83	7	12
96	Left-hemispheric predominance of nigrostriatal deficit in isolated REM sleep behavior disorder. <i>Neurology</i> , 2020 , 94, e1605-e1613	6.5	11
95	Mortality in Parkinson's disease, a 20-year follow-up study. <i>Movement Disorders</i> , 2010 , 25, 661-2	7	11
94	In vivo magnetic resonance imaging of embryonic neural grafts in a rat model of striatonigral degeneration (multiple system atrophy). <i>NeuroImage</i> , 2000 , 12, 209-18	7.9	11

93	Haste makes waste: Decision making in patients with restless legs syndrome with and without augmentation. <i>PLoS ONE</i> , 2017 , 12, e0174793	3.7	11
92	New hopes for disease modification in Parkinson's Disease. <i>Neuropharmacology</i> , 2020 , 171, 108085	5.5	11
91	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. <i>Movement Disorders</i> , 2021 , 36, 681-689	7	11
90	Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. <i>Journal of Parkinson's Disease</i> , 2019 , 9, 681-691	5.3	10
89	Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues. <i>Journal of Neural Transmission</i> , 2017 , 124, 1029-1036	4.3	10
88	Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. <i>Clinical Interventions in Aging</i> , 2012 , 7, 83-8	4	10
87	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018 , 90, 74-82	6.5	10
86	Validation of the Neurogenic Orthostatic Hypotension Ratio with Active Standing. <i>Annals of Neurology</i> , 2020 , 88, 643-645	9.4	9
85	Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. <i>Parkinsonism and Related Disorders</i> , 2020 , 77, 57-63	3.6	9
84	Urinary retention discriminates multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 1926-1928	7	9
83	Abnormal responses to repetitive transcranial magnetic stimulation in multiple system atrophy. <i>Movement Disorders</i> , 2007 , 22, 174-8	7	9
82	Gait and postural disorders in parkinsonism: a clinical approach. <i>Journal of Neurology</i> , 2020 , 267, 3169-3176	5.5	9
81	Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study). <i>Journal of Neural Transmission</i> , 2019 , 126, 1061-1072	4.3	8
80	Diagnostic potential of automated tractography in progressive supranuclear palsy variants. <i>Parkinsonism and Related Disorders</i> , 2020 , 72, 65-71	3.6	8
79	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. <i>Neurology</i> , 2020 , 95, e2854-e2865	6.5	8
78	1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism. <i>Movement Disorders</i> , 2016 , 31, 1925-1927	7	7
77	Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease. <i>International Clinical Psychopharmacology</i> , 2013 , 28, 214-6	2.2	7
76	Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies. <i>Movement Disorders</i> , 2016 , 31, 235-40	7	7

75	Reflection impulsivity perceptual decision-making in patients with restless legs syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 315-322	5.3	6
74	Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. <i>Movement Disorders</i> , 2016 , 31, 1577-1581	7	6
73	Motoric cognitive risk syndrome: multicenter incidence study. <i>Neurology</i> , 2015 , 85, 388-9	6.5	5
72	Towards seeing the visual impairments in Parkinson's disease: protocol for a multicentre observational, cross-sectional study. <i>BMC Neurology</i> , 2019 , 19, 141	3.1	5
71	Relevance of EARLYSTIM in a tertiary movement disorders center. <i>Movement Disorders</i> , 2014 , 29, 1220-17		5
70	Plasma fasting cholesterol profiles and age at onset in Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1974-5	7	5
69	Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome. <i>Nature Medicine</i> , 2001 , 7, 132	50.5	5
68	Time will tell: Decision making in premanifest and manifest Huntington's disease. <i>Brain and Behavior</i> , 2020 , 10, e01843	3.4	5
67	Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2021 , 82, 87-91	3.6	5
66	Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. <i>Clinical Autonomic Research</i> , 2021 , 31, 157-164	4.3	5
65	Reader response: Olfaction and incident Parkinson disease in US white and black older adults. <i>Neurology</i> , 2018 , 90, 940	6.5	5
64	A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021 , 36, 1203-1215	7	5
63	Substantia nigra hypoechogenicity in Friedreich ataxia. <i>Movement Disorders</i> , 2012 , 27, 332-3	7	4
62	Pramipexole extended release in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 1229-34	4.3	4
61	Neuropathologic changes in Parkinson disease with late onset of dementia. <i>Archives of Neurology</i> , 2003 , 60, 452-3; author reply 453-4		4
60	A MDS Evidence-Based Review on Treatments for Huntington's Disease. <i>Movement Disorders</i> , 2021 ,	7	4
59	Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 382-388	2.2	4
58	Neurological outcomes one year after COVID-19 diagnosis: a prospective longitudinal cohort study.. <i>European Journal of Neurology</i> , 2022 ,	6	4

57	Very late-onset pure autonomic failure. <i>Movement Disorders</i> , 2017 , 32, 1106-1108	7	3
56	Application of a Simple Parkinson's Disease Risk Score in a Longitudinal Population-Based Cohort. <i>Movement Disorders</i> , 2020 , 35, 1658-1662	7	3
55	Shaker-related voltage-gated potassium channels Kv1 in human hippocampus. <i>Brain Structure and Function</i> , 2018 , 223, 2663-2671	4	3
54	Insulin signalling: new target for Parkinson's treatments?. <i>Lancet, The</i> , 2017 , 390, 1628-1630	40	3
53	Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 389-396	2.2	3
52	Intensive care management in very old adults: two cases with clostridium tetani infection. <i>Journal of the American Geriatrics Society</i> , 2011 , 59, 552-3	5.6	3
51	Axial myopathy in parkinsonism. <i>Movement Disorders</i> , 2011 , 26, 1569-71	7	3
50	Lewy bodies in patients presenting clinically with Alzheimer disease. <i>Journal of Alzheimer's Disease</i> , 2002 , 4, 327-8	4.3	3
49	Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis.. <i>JAMA Neurology</i> , 2022 ,	17.2	3
48	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [C]PBR28 and Machine Learning Analysis. <i>Movement Disorders</i> , 2021 ,	7	3
47	Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 6-19	2.2	3
46	Characterization of gait variability in multiple system atrophy and Parkinson's disease. <i>Journal of Neurology</i> , 2021 , 268, 1770-1779	5.5	3
45	A Standardized MR Imaging Protocol for Parkinsonism. <i>Movement Disorders</i> , 2020 , 35, 1745-1750	7	3
44	Has Deep Brain Stimulation Changed the Very Long-Term Outcome of Parkinson's Disease? A Controlled Longitudinal Study. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 782-787	2.2	3
43	Augmentation in restless legs syndrome: an eye tracking study on emotion processing. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 1620-1627	5.3	3
42	Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study. <i>Movement Disorders</i> , 2021 , 36, 1464-1466	7	3
41	Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia are more frequent in advanced versus early Parkinson's disease. <i>Sleep</i> , 2021 , 44,	1.1	3
40	Laboratory-Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 322-340 ²	2.2	3

39	Automated segmentation of deep brain nuclei using convolutional neural networks and susceptibility weighted imaging. <i>Human Brain Mapping</i> , 2021 , 42, 4809-4822	5.9	3
38	Automated Analysis of Diffusion-Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 241-245	7	3
37	Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 1052-1060	2.2	3
36	Factors associated with impaired quality of life three months after being diagnosed with COVID-19. <i>Quality of Life Research</i> , 2021 , 1	3.7	3
35	Effects of self-administered cannabidiol in a patient with multiple system atrophy. <i>Clinical Autonomic Research</i> , 2020 , 30, 355-356	4.3	2
34	No effect of age, gender and total intracranial volume on brainstem MR planimetric measurements. <i>European Radiology</i> , 2020 , 30, 2802-2808	8	2
33	Topography of cerebral monoamine transporter availability in families with SCA2 mutations: a voxel-wise [¹²³ I]beta-CIT SPECT analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33, 1084-90	8.8	2
32	The Frontal Assessment Battery in RLS patients with and without augmentation. <i>Sleep Medicine</i> , 2020 , 75, 456-458	4.6	2
31	Towards subgroup-specific risk estimates: A meta-analysis of longitudinal studies on olfactory dysfunction and risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021 , 84, 155-163	3.6	2
30	Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2021 , 85, 30-36	3.6	2
29	The Parkinson disease connectome - insights from new imaging studies. <i>Nature Reviews Neurology</i> , 2021 , 17, 527-528	15	2
28	Birds of a Feather Flock Together: Disadvantageous Decision Making in Augmented Restless Legs Syndrome Patients with and without Impulse Control Disorders. <i>Brain Sciences</i> , 2021 , 11,	3.4	2
27	Leitlinien Chorea/Morbus Huntington für die deutschsprachigen Länder neu Bearbeitet. <i>Aktuelle Neurologie</i> , 2018 , 45, 570-585		2
26	Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.. <i>Movement Disorders</i> , 2022 ,	7	2
25	Letter re: Incident parkinsonism in older adults without Parkinson disease. <i>Neurology</i> , 2017 , 88, 919	6.5	1
24	The footprint of orthostatic hypotension in parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2020 , 77, 107-109	3.6	1
23	Invasive Treatment Strategies in a Patient with PARK 15-Associated Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 434-435	2.2	1
22	Perimenstrual Fluctuations in Two Siblings With Early-Onset Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2014 , 1, 125-127	2.2	1

21	Structural MRI in Idiopathic Parkinson Disease and Parkinsonism 2013 , 105-128		1
20	Managing the Non-Motor Symptoms of Parkinson's Disease 2008 , 91-120		1
19	Imaging markers of disease progression in multiple system atrophy. <i>Future Neurology</i> , 2019 , 14, FNL24	1.5	1
18	Impaired Inhibitory Control of Saccadic Eye Movements in Cervical Dystonia: An Eye-Tracking Study. <i>Movement Disorders</i> , 2021 , 36, 1246-1250	7	1
17	Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?. <i>Movement Disorders</i> , 2021 , 36, 2703-2705	7	1
16	Prodromal Parkinson's disease: hype or hope for disease-modification trials?. <i>Translational Neurodegeneration</i> , 2022 , 11, 11	10.3	1
15	Undetected ophthalmological disorders in Parkinson's disease.. <i>Journal of Neurology</i> , 2022 , 1	5.5	1
14	Eye Tracking in Patients with Parkinson's Disease Treated with Nabilone: Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study. <i>Brain Sciences</i> , 2022 , 12, 661	3.4	1
13	Symptomatic hemiparkinsonism due to extensive middle and posterior fossa arachnoid cyst: case report. <i>BMC Neurology</i> , 2020 , 20, 89	3.1	0
12	The role of arterial spin labeling, a noninvasive MRI perfusion method, in identifying an abnormal cerebral perfusion pattern in Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 1197-1197	7	0
11	Cardiac sympathetic innervation in Parkinson's disease versus multiple system atrophy.. <i>Clinical Autonomic Research</i> , 2022 , 1	4.3	0
10	Differentiating PSP from MSA using MR planimetric measurements: a systematic review and meta-analysis. <i>Journal of Neural Transmission</i> , 2021 , 128, 1497-1505	4.3	0
9	Utility of Nigral Signal Intensity Changes on MR Images to Differentiate Drug-induced Parkinsonism from Parkinson Disease. <i>Radiology</i> , 2016 , 281, 651-652	20.5	
8	Reply to letter: Nonmotor symptoms in subjects without evidence of dopaminergic deficits. <i>Movement Disorders</i> , 2016 , 31, 1588-1589	7	
7	Comment: Autologous mesenchymal stem cells: Hope for patients with multiple system atrophy?. <i>Neurology</i> , 2019 , 93, 25	6.5	
6	Magnetic resonance imaging of multiple system atrophy	167-203	
5	Multiple System Atrophy: Clinical Features and Management. <i>Blue Books of Neurology</i> , 2010 , 34, 340-359		
4	Reply: Restless Legs Syndrome and Parkinson's Disease	<i>Movement Disorders</i> , 2010 , 25, 1314-1315	7

- 3 Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?.
Neurology, **2016**, 87, 2603 6.5
- 2 Extending the Spectrum of Nonmotor Symptoms with Olfaction in Premotor Huntington's Disease:
A Pilot Study. *Neurodegenerative Diseases*, **2020**, 20, 207-211 2.3
- 1 Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive
Supranuclear Palsy". *Movement Disorders*, **2021**, 36, 2208-2209 7